Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer.

Emran AA, Marzese DM, Menon DR, Hammerlindl H, Ahmed F, Richtig E, Duijf P, Sb Hoon D, Schaider H.

Epigenomics. 2019 May 9. doi: 10.2217/epi-2018-0173. [Epub ahead of print]

2.

Human melanoma brain metastases cell line MUG-Mel1, isolated clones and their detailed characterization.

Heitzer E, Groenewoud A, Meditz K, Lohberger B, Liegl-Atzwanger B, Prokesch A, Kashofer K, Behrens D, Haybaeck J, Kolb-Lenz D, Koefeler H, Riedl S, Schaider H, Fischer C, Snaar-Jagalska BE, de'Jong D, Szuhai K, Zweytick D, Rinner B.

Sci Rep. 2019 Mar 11;9(1):4096. doi: 10.1038/s41598-019-40570-1.

3.

Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.

Torrano J, Al Emran A, Hammerlindl H, Schaider H.

Clin Epigenetics. 2019 Mar 8;11(1):43. doi: 10.1186/s13148-019-0644-y. Review.

4.

Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.

Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H.

Cancer Med. 2019 Mar;8(3):1186-1196. doi: 10.1002/cam4.1978. Epub 2019 Feb 21.

5.

A systematic review and meta-analysis of locoregional treatments for in-transit melanoma.

Read T, Lonne M, Sparks DS, David M, Wagels M, Schaider H, Soyer HP, Smithers BM.

J Surg Oncol. 2019 Jun;119(7):887-896. doi: 10.1002/jso.25400. Epub 2019 Feb 7.

PMID:
30734295
6.

The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review.

Deen J, Schaider H.

Australas J Dermatol. 2019 Jan 21. doi: 10.1111/ajd.12992. [Epub ahead of print] Review.

PMID:
30666627
7.

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma.

Laino A, Shepherd B, Atkinson V, Fu H, Soyer HP, Schaider H.

JAAD Case Rep. 2018 Oct 10;4(9):921-923. doi: 10.1016/j.jdcr.2018.06.024. eCollection 2018 Oct. No abstract available.

8.

'Mind your Moles' study: protocol of a prospective cohort study of melanocytic naevi.

Koh U, Janda M, Aitken JF, Duffy DL, Menzies S, Sturm RA, Schaider H, Betz-Stablein B, Prow T, Soyer HP, Green AC.

BMJ Open. 2018 Sep 19;8(9):e025857. doi: 10.1136/bmjopen-2018-025857.

9.

An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes.

Joseph SR, Gaffney D, Barry R, Hu L, Banushi B, Wells JW, Lambie D, Strutton G, Porceddu SV, Burmeister B, Leggatt GR, Schaider H, Dolcetti R, Frazer IH, Saunders NA, Foote M, Soyer HP, Simpson F.

J Invest Dermatol. 2019 Jan;139(1):213-223. doi: 10.1016/j.jid.2018.06.190. Epub 2018 Aug 2.

10.

Distinct histone modifications denote early stress-induced drug tolerance in cancer.

Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H.

Oncotarget. 2017 Dec 24;9(9):8206-8222. doi: 10.18632/oncotarget.23654. eCollection 2018 Feb 2.

11.

Whole-Exome Sequencing of Acquired Nevi Identifies Mechanisms for Development and Maintenance of Benign Neoplasms.

Stark MS, Tan JM, Tom L, Jagirdar K, Lambie D, Schaider H, Soyer HP, Sturm RA.

J Invest Dermatol. 2018 Jul;138(7):1636-1644. doi: 10.1016/j.jid.2018.02.012. Epub 2018 Feb 22. Erratum in: J Invest Dermatol. 2018 Sep;138(9):2085.

PMID:
29476775
12.

Co-culture of human fibroblasts and Borrelia burgdorferi enhances collagen and growth factor mRNA.

Aberer E, Surtov-Pudar M, Wilfinger D, Deutsch A, Leitinger G, Schaider H.

Arch Dermatol Res. 2018 Mar;310(2):117-126. doi: 10.1007/s00403-017-1797-1. Epub 2017 Dec 6.

13.

Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H.

Clin Cancer Res. 2018 Mar 1;24(5):1090-1102. doi: 10.1158/1078-0432.CCR-16-2118. Epub 2017 Dec 1.

14.

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.

Hammerlindl H, Schaider H.

J Cell Commun Signal. 2018 Mar;12(1):133-141. doi: 10.1007/s12079-017-0435-1. Epub 2017 Nov 30. Review.

15.

Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.

Thomas S, Laino A, Sturm R, Nufer K, Lambie D, Shepherd B, Atkinson V, Adams L, Soyer HP, Schaider H.

J Eur Acad Dermatol Venereol. 2018 May;32(5):e176-e177. doi: 10.1111/jdv.14678. Epub 2017 Dec 1. No abstract available.

PMID:
29114959
16.

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.

Keller HR, Zhang X, Li L, Schaider H, Wells JW.

Oncotarget. 2017 Jun 16;8(43):75675-75686. doi: 10.18632/oncotarget.18523. eCollection 2017 Sep 26. Review.

17.

In vitro and in vivo cytotoxic activity of human lactoferricin derived antitumor peptide R-DIM-P-LF11-334 on human malignant melanoma.

Riedl S, Rinner B, Schaider H, Liegl-Atzwanger B, Meditz K, Preishuber-Pflügl J, Grissenberger S, Lohner K, Zweytick D.

Oncotarget. 2017 May 11;8(42):71817-71832. doi: 10.18632/oncotarget.17823. eCollection 2017 Sep 22.

18.

The evolving universe of BRAF mutations in melanoma.

Schaider H, Sturm RA.

Br J Dermatol. 2017 Oct;177(4):893. doi: 10.1111/bjd.15829. No abstract available.

PMID:
29052896
19.

Classifying dermoscopic patterns of naevi in a case-control study of melanoma.

McWhirter SR, Duffy DL, Lee KJ, Wimberley G, McClenahan P, Ling N, Ardigo M, Schaider H, Soyer HP, Sturm RA.

PLoS One. 2017 Oct 17;12(10):e0186647. doi: 10.1371/journal.pone.0186647. eCollection 2017.

20.

Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.

Read T, Webber S, Thomas J, Wagels M, Schaider H, Soyer HP, Smithers BM.

BMJ Open. 2017 Oct 6;7(10):e016816. doi: 10.1136/bmjopen-2017-016816.

21.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

22.

The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.

Tan JM, Tom LN, Jagirdar K, Lambie D, Schaider H, Sturm RA, Soyer HP, Stark MS.

Br J Dermatol. 2018 Jan;178(1):191-197. doi: 10.1111/bjd.15809. Epub 2017 Dec 18.

PMID:
28714107
23.

Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.

Read T, Webber S, Tan J, Wagels M, Schaider H, Soyer HP, Smithers BM.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):2030-2037. doi: 10.1111/jdv.14422. Epub 2017 Jul 13.

PMID:
28626861
24.

Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options.

Richtig G, Aigelsreiter A, Kashofer K, Talakic E, Kupsa R, Schaider H, Richtig E.

Case Rep Oncol. 2016 Sep 22;9(3):543-546. eCollection 2016 Sep-Dec.

25.

Pregnancy as a driver for melanoma.

Richtig G, Byrom L, Kupsa R, Schaider H, Hofmann-Wellenhof R, Wolf IH, Soyer HP, Richtig E.

Br J Dermatol. 2017 Sep;177(3):854-857. doi: 10.1111/bjd.15124. Epub 2017 Jul 12.

PMID:
27718538
26.

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation.

Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaider H, Gabrielli B.

Pigment Cell Melanoma Res. 2016 Jul;29(4):444-52. doi: 10.1111/pcmr.12489.

PMID:
27166757
27.

Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.

Lee S, Duffy DL, McClenahan P, Lee KJ, McEniery E, Burke B, Jagirdar K, Martin NG, Sturm RA, Soyer HP, Schaider H.

Br J Dermatol. 2016 Feb;174(2):356-63. doi: 10.1111/bjd.14291. Epub 2016 Jan 22.

PMID:
26871925
28.

Notch4 Signaling Induces a Mesenchymal-Epithelial-like Transition in Melanoma Cells to Suppress Malignant Behaviors.

Bonyadi Rad E, Hammerlindl H, Wels C, Popper U, Ravindran Menon D, Breiteneder H, Kitzwoegerer M, Hafner C, Herlyn M, Bergler H, Schaider H.

Cancer Res. 2016 Apr 1;76(7):1690-7. doi: 10.1158/0008-5472.CAN-15-1722. Epub 2016 Jan 22.

29.

A distinct expression profile separates Turkish and Australian melanocytic naevi.

Fox C, Schaider H, Akalin T, Turkmen M, Sturm R, Lambie D, Karaarslan IK, Soyer HP, Ozdemir F, Gabrielli B.

Histopathology. 2016 Jul;69(1):151-4. doi: 10.1111/his.12906. Epub 2016 Jan 21. No abstract available.

PMID:
26599517
30.

Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.

Menon DR, Schaider H.

J Invest Dermatol. 2015 Dec;135(12):2923-2925. doi: 10.1038/jid.2015.373.

31.

A systematic review of non-surgical treatments for lentigo maligna.

Read T, Noonan C, David M, Wagels M, Foote M, Schaider H, Soyer HP, Smithers BM.

J Eur Acad Dermatol Venereol. 2016 May;30(5):748-53. doi: 10.1111/jdv.13252. Epub 2015 Aug 24. Review.

PMID:
26299846
32.

Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine.

Riedl S, Leber R, Rinner B, Schaider H, Lohner K, Zweytick D.

Biochim Biophys Acta. 2015 Nov;1848(11 Pt A):2918-31. doi: 10.1016/j.bbamem.2015.07.018. Epub 2015 Aug 1.

33.

Toxicity of oxidized phosphatidylcholines in cultured human melanoma cells.

Ramprecht C, Jaritz H, Streith I, Zenzmaier E, Köfeler H, Hofmann-Wellenhof R, Schaider H, Hermetter A.

Chem Phys Lipids. 2015 Jul;189:39-47. doi: 10.1016/j.chemphyslip.2015.05.007. Epub 2015 May 28.

PMID:
26028612
34.

Gα13 mediates human cytomegalovirus-encoded chemokine receptor US28-induced cell death in melanoma.

Joshi S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, Holmen SL, Otte M, Herlyn M, Waldhoer M, Schaider H.

Int J Cancer. 2015 Sep 15;137(6):1503-8. doi: 10.1002/ijc.29506. Epub 2015 Mar 16.

35.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4545. doi: 10.1038/onc.2014.432. Epub 2015 Jan 26.

PMID:
25619837
36.

BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.

Tan JM, Lin LL, Lambie D, Flewell-Smith R, Jagirdar K, Schaider H, Sturm RA, Prow TW, Soyer HP.

JAMA Dermatol. 2015 Apr;151(4):417-21. doi: 10.1001/jamadermatol.2014.3775.

PMID:
25607474
37.

High-contrast coherent terahertz imaging of porcine tissue via swept-frequency feedback interferometry.

Lim YL, Taimre T, Bertling K, Dean P, Indjin D, Valavanis A, Khanna SP, Lachab M, Schaider H, Prow TW, Peter Soyer H, Wilson SJ, Linfield EH, Giles Davies A, Rakić AD.

Biomed Opt Express. 2014 Oct 17;5(11):3981-9. doi: 10.1364/BOE.5.003981. eCollection 2014 Nov 1.

38.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4448-59. doi: 10.1038/onc.2014.372. Epub 2014 Nov 24. Erratum in: Oncogene. 2015 Aug 20;34(34):4545.

39.

Distribution analyses of acquired melanocytic naevi on the trunk.

Blake T, McClenahan P, Duffy D, Schaider H, McEniery E, Soyer HP.

Dermatology. 2014;228(3):269-75. doi: 10.1159/000358217. Epub 2014 Mar 27.

PMID:
24924527
40.

Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine.

Riedl S, Rinner B, Schaider H, Lohner K, Zweytick D.

Biometals. 2014 Oct;27(5):981-97. doi: 10.1007/s10534-014-9749-0. Epub 2014 May 18.

41.

BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.

McClenahan P, Lin LL, Tan JM, Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Lambie D, Prow TW, Sturm RA, Soyer HP.

JAMA Dermatol. 2014 Oct;150(10):1079-82. doi: 10.1001/jamadermatol.2014.436.

PMID:
24695877
42.

miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages.

Vinod M, Chennamsetty I, Colin S, Belloy L, De Paoli F, Schaider H, Graier WF, Frank S, Kratky D, Staels B, Chinetti-Gbaguidi G, Kostner GM.

Biochim Biophys Acta. 2014 Jun;1841(6):827-35. doi: 10.1016/j.bbalip.2014.02.006. Epub 2014 Mar 3.

43.

NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas.

Deutsch AJ, Rinner B, Wenzl K, Pichler M, Troppan K, Steinbauer E, Schwarzenbacher D, Reitter S, Feichtinger J, Tierling S, Prokesch A, Scheideler M, Krogsdam A, Thallinger GG, Schaider H, Beham-Schmid C, Neumeister P.

Blood. 2014 Apr 10;123(15):2367-77. doi: 10.1182/blood-2013-08-518878. Epub 2014 Feb 19.

44.

TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma.

Menon DR, Wels C, Bonyadi Rad E, Joshi S, Knausz H, Lade-Keller J, Brandner JM, Schaider H.

Pigment Cell Melanoma Res. 2013 Nov;26(6):912-6. doi: 10.1111/pcmr.12139. Epub 2013 Aug 23.

PMID:
23848983
45.

Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma.

Deutsch AJ, Steinbauer E, Hofmann NA, Strunk D, Gerlza T, Beham-Schmid C, Schaider H, Neumeister P.

Mod Pathol. 2013 Feb;26(2):182-94. doi: 10.1038/modpathol.2012.134. Epub 2012 Aug 31.

46.

Naphthoquinones from Onosma paniculata induce cell-cycle arrest and apoptosis in melanoma Cells.

Kretschmer N, Rinner B, Deutsch AJ, Lohberger B, Knausz H, Kunert O, Blunder M, Boechzelt H, Schaider H, Bauer R.

J Nat Prod. 2012 May 25;75(5):865-9. doi: 10.1021/np2006499. Epub 2012 Apr 24.

47.

In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy.

Riedl S, Rinner B, Asslaber M, Schaider H, Walzer S, Novak A, Lohner K, Zweytick D.

Biochim Biophys Acta. 2011 Nov;1808(11):2638-45. doi: 10.1016/j.bbamem.2011.07.026. Epub 2011 Jul 26.

48.

Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelial-mesenchymal transition-like phenotype in melanoma.

Wels C, Joshi S, Koefinger P, Bergler H, Schaider H.

J Invest Dermatol. 2011 Sep;131(9):1877-85. doi: 10.1038/jid.2011.142. Epub 2011 May 19.

49.

The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators.

Koefinger P, Wels C, Joshi S, Damm S, Steinbauer E, Beham-Schmid C, Frank S, Bergler H, Schaider H.

Pigment Cell Melanoma Res. 2011 Apr;24(2):382-5. doi: 10.1111/j.1755-148X.2010.00807.x. Epub 2010 Dec 7. No abstract available.

50.

HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.

Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, Kerl H, Otte M, Schaider H.

J Invest Dermatol. 2010 Jul;130(7):1893-903. doi: 10.1038/jid.2010.45. Epub 2010 Apr 1.

Supplemental Content

Loading ...
Support Center